Evidence map›Paper›PMID 41356374›Full record

ArticleWorld journal of stem cells2025

Cancer cell-dependent increase in senescence-like populations following exosome treatment from bone marrow and induced pluripotent stem cell-derived mesenchymal stem cells.

Nidaa A Ababneh, Sura Nashwan, Razan AlDiqs, Mohammad A Ismail, Ahmed A Abdulelah, Anas H A Abu-Humaidan, Lina AlQirem, Khairallah Al-Abdallat, Talal Al-Qaisi, Tareq Saleh and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nidaa A AbabnehCell Therapy Center, University of Jordan, Amman 11942, Jordan. n.ababneh@ju.edu.jo.
Sura NashwanCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Razan AlDiqsDepartment of Allied Sciences, Faculty of Arts and Sciences, Al-Ahliyya Amman University, Amman 19111, Jordan.
Mohammad A IsmailCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Ahmed A AbdulelahSchool of Medicine, University of Jordan, Amman 11942, Jordan.
Anas H A Abu-HumaidanDepartment of Pathology, Microbiology and Forensic Medicine, School of Medicine, University of Jordan, Amman 11942, Jordan.
Lina AlQiremSchool of Medicine, University of Jordan, Amman 11942, Jordan.
Khairallah Al-AbdallatBone Marrow Transplantation Unit, Jordan University Hospital, Amman 11942, Jordan.
Talal Al-QaisiDepartment of Biomedical Sciences, College of Health Sciences, Abu Dhabi University, Abu Dhabi 59911, United Arab Emirates.
Tareq SalehDepartment of Pharmacology & Therapeutics, College of Medicine & Health Sciences Manama, Arabian Gulf University, Manama 329, Bahrain.
Abdalla AwidiCell Therapy Center, University of Jordan, Amman 11942, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stem cell (MSC) extracellular vesicles, particularly exosomes (Exos), are gaining recognition as promising therapeutic tools for cancer due to their capacity to modulate tumor cell biology. Induced pluripotent stem cell-derived MSCs (iMSCs) revealed therapeutic characteristics compared with conventional MSCs due to their proliferative capacity and enhanced differentiation potential.

aimTo study the impact of Exos derived from iMSCs (iMSC-Exos) and bone marrow MSCs (BMSC-Exos) on PANC1 and MDA-MB-231 cancer cells.

methodsThe iMSCs and BMSCs were characterized based on the International Society for Cellular Therapy (2006) criteria by verifying the expression of MSC-specific markers and their differentiation potential. Exos were isolated from 48-hour conditioned media using sequential ultracentrifugation and characterized based on size, morphology, and expression of surface markers including CD9, CD81, and CD63. PANC1 and MDA-MB-231 cells were treated with the isolated Exos, and their effects on cell proliferation, apoptosis, senescence, and invasion were assessed.

resultsIn PANC1 cells iMSC-Exos sustained antiproliferative activity for 48 hours (35% reduction,

conclusioniMSC-Exos effectively inhibited tumor proliferation and invasion

Indexed as

Bone marrow-derived stromal cellsBreast cancerCell-free cancer therapyExosomesInduced pluripotent stem cell-derived mesenchymal stem cellsPancreatic cancerSenescence-associated secretory phenotype

Identifiers

PMID41356374
PMCPMC12679233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.